公开(公告)号：US20120264919A1

公开(公告)日：2012-10-18

申请号：US13453090

申请日：2012-04-23

Applicant: Laird BLOOM ,  Davinder GILL ,  Yulia VUGMEYSTER ,  Deborah A. YOUNG ,  David LOWE ,  Viia VALGE-ARCHER

Inventor： Laird BLOOM ,  Davinder GILL ,  Yulia VUGMEYSTER ,  Deborah A. YOUNG ,  David LOWE ,  Viia VALGE-ARCHER

IPC: C07K16/28 ,  C12N1/19 ,  C12N5/10 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63

CPC classification number: C07K14/54 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92

Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Abstract translation: 本发明提供与人白细胞介素-21受体（IL-21R）特异性结合的结合蛋白及其抗原结合片段。 结合蛋白可以作为例如IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。 所公开的组合物和方法可用于例如诊断和/或治疗IL-21R相关疾病，例如炎症性疾病，自身免疫疾病，过敏反应，移植排斥反应，癌症和其他免疫系统疾病。

公开(公告)号：US07910105B2

公开(公告)日：2011-03-22

申请号：US11402885

申请日：2006-04-13

Applicant: Deborah A. Young ,  Thomas A. Wynn ,  Mary Collins ,  Michael J. Grusby

Inventor： Deborah A. Young ,  Thomas A. Wynn ,  Mary Collins ,  Michael J. Grusby

IPC: A61K39/395 ,  A61K38/20

CPC classification number: G01N33/6869 ,  A61K33/24 ,  A61K38/13 ,  A61K38/1793 ,  A61K38/20 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/7155 ,  C07K16/244 ,  C07K16/2866 ,  C07K2319/30 ,  G01N2800/00 ,  Y02A50/423 ,  A61K2300/00

Abstract: The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

Abstract translation: 本发明提供了通过测量IL-21和/或IL-21受体（IL-21R）水平的变化来筛选用于治疗，改善或预防纤维化和/或纤维化相关病症的组合物的方法， （例如，IL-21和/或IL-21R蛋白和/或mRNA的表达水平，IL-21和/或IL-21R的活性水平，IL-21与IL-21R的相互作用水平 ）。 本发明还提供了用于治疗纤维化和/或纤维化相关病症的IL-21或IL-21R拮抗剂。 本文还提供了通过测量IL-21和/或IL-21R的水平来诊断，预测和监测纤维化和/或纤维化相关病症的进展（例如，治疗过程）的方法（即，水平 的IL-21和/或IL-21R的活性，IL-21和/或IL-21R的表达水平（例如IL-21和/或IL-21R基因产物的水平）和/或 IL-21与IL-21R的相互作用水平）。

公开(公告)号：US20080241098A1

公开(公告)日：2008-10-02

申请号：US11947425

申请日：2007-11-29

Applicant: Deborah A. Young ,  Mary Collins ,  Kyriaki Dunussi-Joannopoulos ,  Richard Michael O'Hara ,  Marion T. Kasaian ,  Matthew J. Whitters

Inventor： Deborah A. Young ,  Mary Collins ,  Kyriaki Dunussi-Joannopoulos ,  Richard Michael O'Hara ,  Marion T. Kasaian ,  Matthew J. Whitters

IPC: A61K38/20 ,  A61K39/395 ,  A61K39/44 ,  C07K16/46 ,  C12N15/63 ,  C12N5/06 ,  C12P21/00 ,  A61P41/00

CPC classification number: C07K16/2866 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0368 ,  A61K38/1793 ,  A61K49/0008 ,  A61K2039/505 ,  C07K14/7155 ,  C07K2319/30 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2500/02 ,  G01N2800/245

Abstract: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).

Abstract translation: 使用IL-21或IL-21受体（“IL-21R”或“MU-1”）拮抗剂抑制白细胞介素-21（IL-21）/ IL-21受体（MU-1）活性的方法和组合物 披露 IL-21 / IL-21R拮抗剂可用于诱导体内的免疫抑制，例如用于治疗，改善或预防自身免疫性或炎症性疾病，包括例如炎症性肠病（IBD），类风湿性关节炎（RA），移植/ 移植物排斥，牛皮癣，哮喘，纤维化和系统性红斑狼疮（SLE）。

公开(公告)号：US07189400B2

公开(公告)日：2007-03-13

申请号：US09972218

申请日：2001-10-04

Applicant: Laura Carter ,  Matthew J. Whitters ,  Mary Collins ,  Deborah A. Young ,  Debra D. Donaldson ,  Lesile D. Lowe ,  Michelle Unger

Inventor： Laura Carter ,  Matthew J. Whitters ,  Mary Collins ,  Deborah A. Young ,  Debra D. Donaldson ,  Lesile D. Lowe ,  Michelle Unger

IPC: A61K39/00 ,  A61K39/315 ,  A61K38/17

CPC classification number: A61K38/20 ,  A61K38/00 ,  C07K14/715 ,  C07K2319/30

Abstract: Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.

Abstract translation: 提供了通过施用MU-1造血细胞因子受体超家族蛋白质的拮抗剂来抑制受试者的免疫应答的方法。

公开(公告)号：US20090298081A1

公开(公告)日：2009-12-03

申请号：US12472237

申请日：2009-05-26

Applicant: Laird BLOOM ,  Davinder GILL ,  Yulia VUGMEYSTER ,  Deborah A. YOUNG ,  Margot O'TOOLE ,  Heath M. GUAY ,  Karissa K. ADKINS ,  Amy Arlene WEAVER ,  Sadhana JAIN ,  Maya ARAI

Inventor： Laird BLOOM ,  Davinder GILL ,  Yulia VUGMEYSTER ,  Deborah A. YOUNG ,  Margot O'TOOLE ,  Heath M. GUAY ,  Karissa K. ADKINS ,  Amy Arlene WEAVER ,  Sadhana JAIN ,  Maya ARAI

IPC: C12Q1/68 ,  A61K39/395

CPC classification number: G01N33/6869 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  G01N2333/54

Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.

Abstract translation: 本发明提供特异性结合人白细胞介素-21受体（IL-21R）的结合蛋白及其抗原结合片段，包括人抗体，以及使用它们的方法。 结合蛋白可以作为例如IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。 所公开的组合物和方法可以用于例如诊断，治疗和/或预防IL-21R相关疾病，例如炎性疾病，自身免疫疾病，过敏，移植排斥和其它免疫系统疾病。

公开(公告)号：US07198789B2

公开(公告)日：2007-04-03

申请号：US10264634

申请日：2002-10-04

Applicant: Laura Carter ,  Beatriz Carreno ,  Leslie D. Lowe ,  Matthew J. Whitters ,  Kyri Dunussi ,  Mary Collins ,  Margery Ma ,  Deborah A. Young ,  JoAnn S. Witek ,  Glenn Larsen ,  Marion T. Kasaian ,  Debra D. Donaldson ,  Michelle Unger

Inventor： Laura Carter ,  Beatriz Carreno ,  Leslie D. Lowe ,  Matthew J. Whitters ,  Kyri Dunussi ,  Mary Collins ,  Margery Ma ,  Deborah A. Young ,  JoAnn S. Witek ,  Glenn Larsen ,  Marion T. Kasaian ,  Debra D. Donaldson ,  Michelle Unger

IPC: A61K39/00 ,  A61K39/395 ,  A61K38/17

CPC classification number: C07K14/715 ,  A61K38/1793 ,  A61K38/20 ,  C07K2319/30

Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

Abstract translation: 使用IL-21或IL-21受体（“IL-21R”或“MU-1”）的激动剂或拮抗剂调节白细胞介素-21（IL-21）/ IL-21受体（MU-1）活性的方法和组合物 ，被披露。 IL-21 / IL-21R拮抗剂可用于在体内诱导免疫抑制，例如用于治疗或预防免疫细胞相关病理学（例如，与一种或多种成熟T细胞的异常活性相关的病理学（成熟CD8 +，成熟 CD4 + T细胞），成熟NK细胞，B细胞，巨噬细胞和巨核细胞，包括移植排斥反应和自身免疫性疾病。 IL-21 / IL-21R激动剂可以自身使用或与抗原组合使用，例如作为佐剂（例如，疫苗佐剂），以在体内上调免疫应答，例如使用 在治疗癌症和感染性疾病。

公开(公告)号：US20110142833A1

公开(公告)日：2011-06-16

申请号：US13030840

申请日：2011-02-18

Applicant: Deborah A. YOUNG ,  Thomas A. Wynn ,  Mary Collins ,  Michael J. Grusby

Inventor： Deborah A. YOUNG ,  Thomas A. Wynn ,  Mary Collins ,  Michael J. Grusby

IPC: A61K38/17 ,  A61K39/395 ,  A61P11/00 ,  A61P1/16 ,  A61P17/00 ,  A61P29/00 ,  C12Q1/02

CPC classification number: G01N33/6869 ,  A61K33/24 ,  A61K38/13 ,  A61K38/1793 ,  A61K38/20 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/7155 ,  C07K16/244 ,  C07K16/2866 ,  C07K2319/30 ,  G01N2800/00 ,  Y02A50/423 ,  A61K2300/00

Abstract: The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

Abstract translation: 本发明提供了通过测量IL-21和/或IL-21受体（IL-21R）水平的变化来筛选用于治疗，改善或预防纤维化和/或纤维化相关病症的组合物的方法， （例如，IL-21和/或IL-21R蛋白和/或mRNA的表达水平，IL-21和/或IL-21R的活性水平，IL-21与IL-21R的相互作用水平 ）。 本发明还提供了用于治疗纤维化和/或纤维化相关病症的IL-21或IL-21R拮抗剂。 本文还提供了通过测量IL-21和/或IL-21R的水平来诊断，预测和监测纤维化和/或纤维化相关病症的进展（例如，治疗过程）的方法（即，水平 的IL-21和/或IL-21R的活性，IL-21和/或IL-21R的表达水平（例如IL-21和/或IL-21R基因产物的水平）和/或 IL-21与IL-21R的相互作用水平）。

公开(公告)号：US20100297151A1

公开(公告)日：2010-11-25

申请号：US12353812

申请日：2009-01-14

Applicant: Viia Valge-Archer ,  Andrew James Williams ,  Deborah A. Young ,  Matthew J. Whitters ,  Mary Collins ,  Joann Witek

Inventor： Viia Valge-Archer ,  Andrew James Williams ,  Deborah A. Young ,  Matthew J. Whitters ,  Mary Collins ,  Joann Witek

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  C07H21/00 ,  C12N15/63 ,  C12N5/10 ,  C12N1/21 ,  C12N1/19 ,  C12P21/02 ,  C12N5/07 ,  A61P29/00 ,  A61P37/02 ,  A61P17/06 ,  A61P1/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/622

Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Abstract translation: 本申请提供了特异性结合人白细胞介素-21受体（IL-21R）的人抗体及其抗原结合片段。 抗体可以作为IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。 所公开的组合物和方法可用于例如诊断，治疗或预防炎性疾病，自身免疫疾病，过敏，移植排斥，癌症和其他免疫系统疾病。

公开(公告)号：US4883654A

公开(公告)日：1989-11-28

申请号：US254152

申请日：1988-10-06

Applicant: Deborah A. Young

Inventor： Deborah A. Young

IPC: A61K8/37 ,  A61K8/86 ,  A61Q1/10 ,  A61Q9/04

CPC classification number: A61K8/86 ,  A61K8/37 ,  A61K8/375 ,  A61Q1/10 ,  A61Q9/04 ,  A61K2800/75

Abstract: A toiletry formulation is provided for cosmetic use, in the form of a stable, spreadable lotion or cream incorporating a skin adherent base possessing non-irritant characteristics compatible with mucous membranes, including emulsifying agents, a skin protectant, a mild germicide to inhibit microbial growth in the formulation, and a combination of desensitizing agents for application to selected areas of the skin of a user, prior to mechanical hair depilation, such as plucking of the eyebrows, in order to minimize reaction of the skin and the local generation of pain in the plucking process.

Abstract translation: 提供了一种用于化妆品使用的化妆品制剂，其为稳定的，可涂抹的洗剂或霜剂的形式，其包含具有与粘膜相容的非刺激性特征的皮肤粘附基质，包括乳化剂，皮肤保护剂，温和杀菌剂以抑制微生物生长 在制剂中的组合以及在使用者的皮肤的选定区域之前的脱敏剂的组合，在机械毛发脱毛之前，例如拔除眉毛，以使皮肤的反应和局部的疼痛发生最小化 采摘过程。

公开(公告)号：US08178097B2

公开(公告)日：2012-05-15

申请号：US12472237

申请日：2009-05-26

Applicant: Laird Bloom ,  Davinder Gill ,  Yulia Vugmeyster ,  Deborah A. Young ,  Margot O'Toole ,  Heath M. Guay ,  Karissa K. Adkins ,  Amy Arlene Weaver ,  Sadhana Jain ,  Maya Arai

Inventor： Laird Bloom ,  Davinder Gill ,  Yulia Vugmeyster ,  Deborah A. Young ,  Margot O'Toole ,  Heath M. Guay ,  Karissa K. Adkins ,  Amy Arlene Weaver ,  Sadhana Jain ,  Maya Arai

IPC: A61K39/395 ,  C07K16/28

CPC classification number: G01N33/6869 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  G01N2333/54

Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.

Abstract translation: 本发明提供特异性结合人白细胞介素-21受体（IL-21R）的结合蛋白及其抗原结合片段，包括人抗体，以及使用它们的方法。 结合蛋白可以作为例如IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。 所公开的组合物和方法可以用于例如诊断，治疗和/或预防IL-21R相关疾病，例如炎性疾病，自身免疫疾病，过敏，移植排斥和其它免疫系统疾病。